Drug General Information
Drug ID
D07TMR
Former ID
DNC001687
Drug Name
ISIS 23722
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [523959]
Company
Isis Pharmaceuticals
Target and Pathway
Target(s) Baculoviral IAP repeat-containing protein 5 Target Info Modulator
KEGG Pathway Hippo signaling pathway
Hepatitis B
Pathways in cancer
Colorectal cancer
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Angiogenesis
Pathway Interaction Database Aurora B signaling
Validated targets of C-MYC transcriptional activation
FOXM1 transcription factor network
Aurora A signaling
Reactome Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
Mitotic Prometaphase
WikiPathways IL-4 Signaling Pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Apoptosis
Interleukin-11 Signaling Pathway
Apoptosis Modulation and Signaling
References
Ref 523959ClinicalTrials.gov (NCT01630733) A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.